Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-09-17 | Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine... She also brings to the Board valuable perspective and insights from her service on the boards of directors of Texas Instruments and Celgene, including their respective Audit Committees. |
| 2014-09-16 | As a former executive officer of Schering-Plough and a licensed pharmacist, Ms. Cox brings to the Board substantial experience in the pharmaceutical aspects of our business. |
| 2015-09-15 | Ms. Cox has served as Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, since 2010 and as Chairman of Humacyte since 2013. ... Through her role as a former executive officer of Schering-Plough and a licensed pharmacist and now with Humacyte, Ms. Cox brings to the Board substantial experience in healthcare, particularly the pharmaceutical aspects of our business. |
| 2016-09-16 | Ms. Cox has served as Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, since 2010 ... She brings to the Board substantial expertise in healthcare, particularly the pharmaceutical and international aspects of our business. |
| 2017-09-21 | Ms. Cox has served as Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, since 2010 and as Chairman of Humacyte since 2013. She previously served as Executive Vice President and President of Global Pharmaceuticals at Schering-Plough Corporation, a multinational branded pharmaceutical manufacturer, from 2003 until its merger with Merck & Co. in 2009. |
| 2018-09-26 | Ms. Cox serves as Executive Chairman of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine... She was Executive Vice President and President of Global Pharmaceuticals at Schering-Plough Corporation... She also brings to the Board valuable perspectives and insights from her service on the boards of directors of Celgene, including its Compensation and Development Committee, and Texas Instruments, including its Compensation Committee. |
| 2019-09-20 | Ms. Cox served as Chairman and Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, from 2010 to 2018 and as its Executive Chairman from 2018 to 2019. She was Executive Vice President and President of Global Pharmaceuticals at Schering-Plough Corporation, a multinational branded pharmaceutical manufacturer, from 2003 until its merger with Merck & Co. in 2009. |
| 2020-09-23 | Ms. Cox served as Chairman and Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine... She also brings to the Board and to her role chairing our Human Resources and Compensation Committee, valuable perspectives and insights from her service on the boards of directors of Selecta Biosciences and Texas Instruments and prior service on the Array BioPharma, Celgene and electroCore boards. |
| 2021-09-23 | Ms. Cox served as Chairman and Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, from 2010 to 2018 and as its Executive Chairman from 2018 to 2019. She was Executive Vice President and President of Global Pharmaceuticals at Schering-Plough Corporation, a multinational branded pharmaceutical manufacturer, from 2003 until its merger with Merck & Co. in 2009. |
| 2022-09-28 | Ms. Cox served as Chairman and CEO of Humacyte, Inc., and EVP and President of Global Pharmaceuticals at Schering-Plough Corporation. She brings substantial expertise in healthcare and pharmaceutical industry but no mention of software or technical skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2016-03-09 | As chairman (2013-present), CEO and a director (2010-present) of Humacyte, Inc., has gained first-hand experience in managing large, multinational organizations focused on medical-related markets. |
| 2017-03-06 | As chairman (2013-present), CEO and a director (2010-present) of Humacyte, Inc., has gained first-hand experience in managing large, multinational organizations. |
| 2018-03-13 | As chairman (2013-present), CEO and a director (2010-present) of Humacyte, Inc., has gained first-hand experience in managing large, multinational organizations. |
| 2019-03-12 | Ms. Cox has gained first-hand experience managing large, multinational organizations focused on medical-related markets. |
| 2020-03-10 | Carrie S. Cox, Former chairman and chief executive officer of Humacyte, Inc. |
| 2021-03-09 | Ms. Cox was the executive chair of Humacyte, Inc. from 2018 to 2019. |
| 2022-03-15 | Carrie S. Cox, Former chairman and chief executive officer of Humacyte, Inc. |
| 2023-03-14 | Carrie S. Cox, Former chairman and chief executive officer of Humacyte, Inc. |
| 2024-03-12 | Carrie S. Cox, Former chairman and chief executive officer of Humacyte, Inc. |
Data sourced from SEC filings. Last updated: 2025-05-12